Case Report: When dual immune checkpoint blockade strikes back: cadonilimab-induced hypersensitivity in solid tumors — a case series and review
BackgroundImmune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, but immune-related hypersensitivity reactions remain a clinical concern. Cadonilimab, a novel PD-1/CTLA-4 bispecific antibody, has demonstrated encouraging antitumor effi…